Capecitabine: the new generation of fluoropyrimidines in colorectal cancer
- 1 December 2004
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 4 (6) , 947-955
- https://doi.org/10.1586/14737140.4.6.947
Abstract
Colorectal cancer is the second leading cause of cancer death in the USA and fluoropyrimidines have been the mainstay of treatment for over 40 years. Currently, capecitabine is the only orally available fluoropyrimidine approved for treatment in the USA. As a single agent it has demonstrated activity and equivalence to 5-fluorouracil (5-FU) intravenous administration via the Mayo Clinic regimen, in both the metastatic and adjuvant settings. Ongoing clinical trials are evaluating the efficacy of capecitabine in combination with oxaliplatin and irinotecan as more convenient substitutes for infusional 5-FU in the 5-FU/leucovorin/oxaliplatin and 5-FU/irinotecan regimens.Keywords
This publication has 17 references indexed in Scilit:
- Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon CancerNew England Journal of Medicine, 2004
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- XELOX (Capecitabine Plus Oxaliplatin): Active First-Line Therapy for Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2004
- Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabineCancer, 2004
- Capecitabine-induced Potentiation of WarfarinClinical Oncology, 2003
- Randomized Multicenter Phase II Trial of Two Different Schedules of Capecitabine Plus Oxaliplatin as First-Line Treatment in Advanced Colorectal CancerJournal of Clinical Oncology, 2003
- Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patientsCancer Chemotherapy and Pharmacology, 2002
- Clinical Pharmacokinetics of CapecitabineClinical Pharmacokinetics, 2001
- Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patientsCancer Chemotherapy and Pharmacology, 2000
- Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patientsCancer Chemotherapy and Pharmacology, 1999